S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
NASDAQ:TCRR

TCR2 Therapeutics - TCRR Stock Forecast, Price & News

$1.14
-0.04 (-3.39%)
(As of 12/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.12
▼
$1.19
50-Day Range
$1.14
▼
$1.81
52-Week Range
$1.12
▼
$5.26
Volume
454,556 shs
Average Volume
427,255 shs
Market Capitalization
$44.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

TCR2 Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
864.9% Upside
$11.00 Price Target
Short Interest
Healthy
4.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.65
Upright™ Environmental Score
News Sentiment
-0.24mentions of TCR2 Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$50,167 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.10) to ($2.37) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.69 out of 5 stars

Medical Sector

66th out of 1,034 stocks

Biological Products, Except Diagnostic Industry

8th out of 172 stocks

See Top Rated MarketRank™ Stocks Here
TCRR stock logo

About TCR2 Therapeutics (NASDAQ:TCRR) Stock

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Receive TCRR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRR Stock News Headlines

December 9, 2022 | americanbankingnews.com
Garry E. Menzel Sells 8,530 Shares of TCR2 Therapeutics Inc. (NASDAQ:TCRR) Stock
December 6, 2022 | americanbankingnews.com
Insider Selling: TCR2 Therapeutics Inc. (NASDAQ:TCRR) CEO Sells 8,408 Shares of Stock
December 2, 2022 | americanbankingnews.com
Short Interest in TCR2 Therapeutics Inc. (NASDAQ:TCRR) Decreases By 35.1%
November 23, 2022 | finance.yahoo.com
TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference
November 11, 2022 | finance.yahoo.com
Down 16.6% in 4 Weeks, Here's Why You Should You Buy the Dip in TCR2 Therapeutics Inc. (TCRR)
November 8, 2022 | finanznachrichten.de
TCR2 Therapeutics: TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 8, 2022 | finance.yahoo.com
TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 7, 2022 | finance.yahoo.com
TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of Cancer
November 6, 2022 | finance.yahoo.com
Is TCR2 Therapeutics (NASDAQ:TCRR) In A Good Position To Deliver On Growth Plans?
September 28, 2022 | finance.yahoo.com
TCR2 Therapeutics Shares Jump After Additional Reponses in Ovarian Cancer, Mesothelioma
September 28, 2022 | seekingalpha.com
TCR2 Therapeutics stock rises 16% as cell therapy for solid tumors shows promise in trial
September 28, 2022 | finance.yahoo.com
gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma
September 27, 2022 | finance.yahoo.com
TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors
September 26, 2022 | finance.yahoo.com
TCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
August 19, 2022 | seekingalpha.com
TCR² Therapeutics: Betting On A Solid Reversal
August 8, 2022 | finance.yahoo.com
TCR² Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 8, 2022 | finance.yahoo.com
What Kind Of Shareholders Hold The Majority In TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) Shares?
August 8, 2022 | americanbankingnews.com
TCR2 Therapeutics Inc. (NASDAQ:TCRR) Given Average Rating of "Moderate Buy" by Brokerages
June 27, 2022 | marketwatch.com
TCR2 Therapeutics Names Eric Sullivan Chief Financial Officer >TCRR
June 27, 2022 | finance.yahoo.com
TCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial Officer
May 30, 2022 | finance.yahoo.com
Will TCR2 Therapeutics (NASDAQ:TCRR) Spend Its Cash Wisely?
May 12, 2022 | finance.yahoo.com
TCR² Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
March 24, 2022 | marketwatch.com
TCR2 Therapeutics Shares Rise 17% on 4Q Results, Trial Progress
March 22, 2022 | seekingalpha.com
TCR2 Therapeutics GAAP EPS of -$0.72 beats by $0.04
March 22, 2022 | finance.yahoo.com
TCR² Therapeutics Reports Fourth Quarter 2021 Financial Results and Provides Corporate Update
See More Headlines
Receive TCRR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRR Company Calendar

Last Earnings
11/08/2022
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/28/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCRR
CUSIP
N/A
CIK
1750019
Web
www.tcr2.com
Phone
(617) 949-5200
Fax
N/A
Employees
137
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+864.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-99,810,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-49.52%
Return on Assets
-38.79%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.02
Quick Ratio
5.02

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.36 per share
Price / Book
0.15

Miscellaneous

Outstanding Shares
38,657,000
Free Float
28,989,000
Market Cap
$44.07 million
Optionable
Not Optionable
Beta
1.71

Key Executives

  • Dr. Garry E. Menzel M.B.A. (Age 58)
    Ph.D., Pres, CEO & Director
    Comp: $916.8k
  • Dr. Patrick A. Baeuerle Ph.D. (Age 64)
    Founder & Member of the Advisory Board
    Comp: $47.02k
  • Mr. Peter Olagunju (Age 44)
    Chief Technical Officer
    Comp: $307.42k
  • Dr. Alfonso Quintas Cardama M.D. (Age 51)
    Chief Medical Officer
    Comp: $668.6k
  • Mr. Richard Roomberg
    VP of Corp. Controller
  • Mr. Eric M. Sullivan CPA (Age 42)
    Chief Financial Officer
  • Carl Mauch
    Sr. Director of Investor Relations & Corp. Communications
  • Ms. Margaret Siegel J.D.
    Head of Legal & Corp. Sec.
  • Dr. Angela Justice Ph.D. (Age 48)
    Chief People Officer
  • Dr. Rosemary Harrison Ph.D. (Age 39)
    Chief Bus. & Strategy Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TCRR Stock - Frequently Asked Questions

Should I buy or sell TCR2 Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TCRR shares.
View TCRR analyst ratings or view top-rated stocks.

What is TCR2 Therapeutics' stock price forecast for 2023?

3 Wall Street analysts have issued twelve-month target prices for TCR2 Therapeutics' stock. Their TCRR share price forecasts range from $5.00 to $18.00. On average, they anticipate the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 873.5% from the stock's current price.
View analysts price targets for TCRR or view top-rated stocks among Wall Street analysts.

How have TCRR shares performed in 2022?

TCR2 Therapeutics' stock was trading at $4.66 at the start of the year. Since then, TCRR shares have decreased by 75.8% and is now trading at $1.13.
View the best growth stocks for 2022 here.

Are investors shorting TCR2 Therapeutics?

TCR2 Therapeutics saw a drop in short interest in November. As of November 15th, there was short interest totaling 1,240,000 shares, a drop of 35.1% from the October 31st total of 1,910,000 shares. Based on an average daily trading volume, of 223,300 shares, the days-to-cover ratio is presently 5.6 days. Approximately 4.0% of the company's stock are short sold.
View TCR2 Therapeutics' Short Interest.

When is TCR2 Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our TCRR earnings forecast.

How were TCR2 Therapeutics' earnings last quarter?

TCR2 Therapeutics Inc. (NASDAQ:TCRR) released its earnings results on Tuesday, November, 8th. The company reported ($0.79) earnings per share for the quarter, topping analysts' consensus estimates of ($0.83) by $0.04.

What other stocks do shareholders of TCR2 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI).

When did TCR2 Therapeutics IPO?

(TCRR) raised $76 million in an initial public offering on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

What is TCR2 Therapeutics' stock symbol?

TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

Who are TCR2 Therapeutics' major shareholders?

TCR2 Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Tang Capital Management LLC (9.68%), Vanguard Group Inc. (3.71%), BlackRock Inc. (2.65%), Renaissance Technologies LLC (1.83%), Two Sigma Advisers LP (1.02%) and Dimensional Fund Advisors LP (0.85%). Insiders that own company stock include Alfonso Quintas Cardama, Garry E Menzel, Mayur Ian Somaiya, Morana Jovan-Embiricos, Neil W Gibson and Robert Hofmeister.
View institutional ownership trends.

How do I buy shares of TCR2 Therapeutics?

Shares of TCRR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TCR2 Therapeutics' stock price today?

One share of TCRR stock can currently be purchased for approximately $1.13.

How much money does TCR2 Therapeutics make?

TCR2 Therapeutics (NASDAQ:TCRR) has a market capitalization of $43.69 million. The company earns $-99,810,000.00 in net income (profit) each year or ($3.09) on an earnings per share basis.

How many employees does TCR2 Therapeutics have?

The company employs 137 workers across the globe.

How can I contact TCR2 Therapeutics?

TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The official website for the company is www.tcr2.com. The company can be reached via phone at (617) 949-5200 or via email at investors@tcr2.com.

This page (NASDAQ:TCRR) was last updated on 12/9/2022 by MarketBeat.com Staff